Network identification

PURI

https://redirect.ema.europa.eu/resource/11190

Network ID

11190

Network name and Acronym

Optimum Patient Care (OPC) Network

Network countries

United Kingdom (Northern Ireland)

Network website

ENCePP partner

Yes
Network description
Optimum Patient Care is a social enterprise supporting medical research and services to improve the diagnosis,treatment and care of chronic diseases within Primary Care. As a result of our comprehensive network of over 550 GP surgeries in the UK,we can deliver Primary Care research support and bespoke data sets for academic research,extracted as IG-Compliant data extractions from our partner practices. The Optimum Patient Care Research Database forms one of the largest respiratory databases in the world.
Network details
Network primary therapeutic area:
Cardiovascular diseases
Liver disease
Medical devices
Respiratory diseases
Network funding:
EU institutional research programme
Non-for-profit organisation (e.g. charity)
Other
Pharmaceutical company and other private sector 

Contact

Institutions that are part of this network

Cambridge Real-Life Research Organisation (CRO)
Observational & Pragmatic Research Institute Pte (OPRI)
General Practitioners Research Institute (GPRI)

Studies conducted by the network

A pragmatic, cluster randomized trial evaluating the impact of an enhanced adherence package (dual bronchodilator+add-on+app) on time to treatment failure and other clinical outcomes in exacerbating COPD patients with poor adherence to mono or dual therapy over one year (MAGNIFY)
Addressing the burden of respiratory disease in General Practice: A real-life implementation study focusing on high risk asthma and COPD patients
Biologic Usage Patterns, Clinical Outcomes and Healthcare Resource Utilization (CLEAR)
Biologics in severe asthma: utilization patterns, causes for discontinuation and switches
Biomarker Relatability in the International Severe Asthma Registry (BRISAR)
Breathlessness Rapid Evaluation and THErapy (BREATHE)
Characterisation of the Australian adult population living with asthma: Exacerbation frequency, long-term OCS use and adverse effects.
Characteristics of type 2 asthma phenotypes and oral corticosteroid (OCS) use in the International Severe Asthma Registry (ISAR) (STAR)
CLinical oUtcomes before and after biologic treatMent by bIologic class, by iNdividuAl biologic, and by subgroups of baseliNe characTeristics (LUMINANT)
Defining and Characterizing Responders to Biologic Treatment (BEAM)
Demographic and Clinical Characteristics of Severe Asthma Patients Worldwide
Descriptive Study of the Incidence of Malignancy in Patients with Severe Asthma Overall and Among Those Receiving Benralizumab and Other Therapies, a Post Authorization Safety Study
Development and validation of a risk prediction tool for oral corticosteroid adverse outcomes in asthma, based on real-world exposure information
Effectiveness across severe asthma biologic classes (Anti-IL-5 vs Anti IgE) in patients eligible for both (FIRE)
EffectIveness of bioloGics (by classes) in patieNts with dIfferent combination of T2 biomarkErs (IGNITE)
ImPact of comoRbidity In Severe asthMa patients (PRISM)
Impact of Initiating Biologics In Patients on Long-Term OCS Or Frequent Rescue Steroids (GLITTER)
International Severe Asthma Registry (ISAR)
Onset of asthma in severe asthma patients (PATH)
Patient characteristics and treatment pathways in patients with COPD initiated on ICS/LABA/LAMA and LABA/LAMA treatment
Patient characteristics, treatment patterns, clinical outcomes, and health care resource utilization in severe asthma subgroups: A retrospective analysis of the International Severe Asthma Registry (EVEREST)
PhEnotypic Characteristics, coMorBidities and response to thErapeutic inteRventions associated with non-type 2 asthma (EMBER)
Predicting Asthma Attacks in Primary Care with Machine Learning
Similarity-based approaches to identifying risk of future asthma attack using UK primary care data
Studying the value of fractional exhaled Nitric Oxide and blood eosinophils as biomarkers in predicting which patients will suffer from more frequent asthma exacerbations, and evaluating the subsequent healthcare resource utilisation (Assessing RIsk of exAcerbation (ARIA))
Sustainability of the Achieving Clinical Audits with Electronic Records (ACAER) Asthma and COPD Quality Improvement Program on Patient Outcomes
The Characterization and Comparison of Eosinophilic and Non-eosinophilic Phenotypes of Severe Asthma
The prevalence of comorbidities in COPD patients, and their impact on health status and COPD symptoms in primary care patients
Understanding high-risk COPD: Analysis of real-world data to investigate characteristics and outcomes in patients with high-risk COPD. (OPRI 2306: High Risk COPD)